ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.

TiGenix has dusted off its plan to file for an IPO on Nasdaq and brought in a new set of underwriters.

It has discontinued lead Phase IIb maturation inhibitor BMS-955176, which it bought from BMS, and COPD candidate losmapimod.

Biogen is aggressively pursuing neurodegenerative diseases, such as spinal muscular atrophy and Alzheimer’s disease.

An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.

Verona Pharma has secured funding for a Phase IIa trial of its PDE3/PDE4 inhibitor RPL554 in cystic fibrosis patients.

After FDA inspections turned up “limited to no reporting” of injuries or deaths stemming from the use of medical devices at 17 hospitals, the agency is setting…

Teva and IBM have formed a three-year, Watson-enabled drug repurposing collaboration

A new study has shown promise in mice for an experimental drug for Alzheimer's disease.